VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

Track this case

Case overview

Case Number:

1:19-md-02875

Court:

New Jersey

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

Renee Marie Bumb

Firms

Companies

Sectors & Industries:

April 08, 2025
Expert And 'Worthlessness Theory' Ejected In Valsartan MDL

Patients and insurers who claim they were ripped off when purchasing the contaminated blood pressure medication Valsartan won't be able to argue that the drug was worthless as a matter of law, a New Jersey federal judge overseeing the multidistrict litigation has ruled, casting doubt that the plaintiffs will secure a full refund for their purchase.
August 05, 2024
Chinese Drug Co. Says Sanctions In Valsartan MDL Too Harsh

Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. told a New Jersey federal court Friday that sanctions authorizing two adverse jury instructions in multidistrict litigation over generic drugs contaminated with carcinogens should be overturned, arguing the plaintiffs did not allege the bad faith required for such a harsh penalty.
May 14, 2024
Chinese Drug Co. Sanctioned After 'Tortuous' 3-Year Info Fight

Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. has been hit with sanctions after its chief executive officer failed to sit for a court-ordered deposition in sprawling multidistrict litigation taking place in New Jersey over generic drugs that U.S. authorities say were contaminated with carcinogens.
February 08, 2023
Consumers And Insurers Get Class Cert. In Valsartan MDL

A New Jersey federal judge on Wednesday certified classes of consumers and insurers who claim they lost money by purchasing the contaminated blood pressure drug Valsartan, as well as two classes of consumers seeking medical monitoring for cancer potentially caused by the drug.
April 05, 2022
Valsartan MDL Judge OKs Out-Of-State Litigants, More Claims

A New Jersey federal judge ruled Tuesday that multidistrict litigation against drug manufacturers, pharmacies and wholesalers over carcinogens in blood pressure drugs can expand to include out-of-state litigants and warranty claims under laws in nearly two dozen jurisdictions.
December 22, 2021
Judge Overrules 'State Secrets' Concerns In Valsartan MDL

A New Jersey federal judge backed a special master's order that Zhejiang Huahai Pharmaceutical Co. Ltd. must produce documents it sought to shield in multidistrict litigation over blood pressure drugs such as valsartan, warning that parties can't exploit uncertainties in foreign state secrets laws to thwart U.S. lawsuits.
June 22, 2021
Chinese Drug Co. Chief Must Testify In Tainted Valsartan MDL

The special master in multidistrict litigation alleging that pharmaceutical companies sold generic drugs containing the active ingredient valsartan that were tainted with carcinogens ruled on Tuesday that the president of Zhejiang Huahai Pharmaceutical Co. Ltd. can't be blocked from giving a deposition in the case.
January 29, 2021
Drugmakers Must Face Fraud Claims In Valsartan MDL

A New Jersey federal judge said Friday he won't toss fraud claims against drug manufacturers, but will toss the claims against wholesalers and pharmacies, in multidistrict litigation alleging they took part in distributing generic drugs containing the active ingredient valsartan that were tainted with carcinogens.
January 25, 2021
Drugmakers Must Face Warranty Claims In Valsartan MDL

A New Jersey federal judge has said manufacturers, wholesalers and pharmacies cannot escape warranty claims in multidistrict litigation alleging they took part in distributing generic drugs containing the active ingredient valsartan that were tainted with carcinogens, finding that the drugs' names and the purported contamination kept certain claims alive.
January 12, 2021
Consumers Can't Bring Out-Of-State Claims in Valsartan MDL

A New Jersey federal judge said Tuesday that consumers in the multidistrict litigation over alleged contamination of the blood pressure drug valsartan don't have standing to bring claims under the laws of states they don't live in.

← Previous
1
2
Next →